Comorbidities, Endocrine Medications, and Mortality in Prader–Willi Syndrome—A Swedish Register Study
Journal of Clinical Medicine · 16.02.2025 · 14 (4) · 1307
DOI: 10.3390/jcm14041307 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 16.02.2025. Verfasst von Julia Giesecke und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine and Surgery, Karolinska Institute, 171 77 Stockholm, Sweden. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Childhood Cancer Fund, Swedish Research Council, Swedish Cancer Society.
Abstract (Originalsprache)
Background
Prader–Willi Syndrome (PWS) is a rare, genetic, multi-systemic disorder. Its main characteristics are muscular hypotonia, behavioral problems, intellectual disability, endocrine deficiencies, hyperphagia, and a high risk of morbid obesity and related comorbidities. This study aimed to investigate the rate of comorbidity, prescription of endocrine medications, and mortality in individuals with PWS compared to the general population.
Methods
The association between PWS and outcomes were investigated in a matched cohort study of individuals born in the period of 1930–2018 with data from Swedish national health and welfare registers. Each individual was matched with 50 non-PWS comparisons. The associations between PWS, outcomes and prescribed endocrine medications were estimated through Cox proportional hazard models, presented as Hazard Ratios (HR) with 95% Confidence Intervals (CIs).
Results
Among 360 individuals (53% men) with PWS, 16% had diabetes mellitus, 6% heart failure, 4% vein thrombosis, 2% atrial fibrillation, 2% coronary heart disease, and 1% pulmonary embolism. Individuals with PWS had an increased rate of heart failure (HR: 23.85; 95% CI: 14.09–40.38), diabetes mellitus (HR: 17.49; 95% CI: 12.87–23.74), vein thrombosis (HR: 10.44; 95% CI: 5.69–19.13), pulmonary embolism (HR: 5.77; 95% CI: 2.27–14.67), atrial fibrillation (HR: 5.19; 95% CI: 2.48–10.86), and coronary heart disease (HR: 3.46; 95% CI: 1.50–7.97) compared to non-PWS individuals. Somatotropin was prescribed in 63%, antidiabetics in 18%, and thyroid hormones in 16% of the PWS individuals (
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Medicine and Surgery, Karolinska Institute, 171 77 Stockholm, Sweden.
- Department of Endocrinology, Karolinska University Hospital, 171 76 Stockholm, Sweden.
- Department of Endocrinology, St Göran's Hospital, 112 19 Stockholm, Sweden.
- Department of Radiology, Karolinska University Hospital, 171 76 Stockholm, Sweden.
- Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institute, 171 77 Stockholm, Sweden.
- Department of Clinical Genetics and Genomics, Karolinska University Hospital, 171 76 Stockholm, Sweden.
ORCID-Profile: Maria Petersson
Förderung
- Swedish Childhood Cancer Fund
- Swedish Research Council
- Swedish Cancer Society
- Cancer Society of Stockholm
- Stiftelsen Frimurare Barnhuset i Stockholm, the Hållsten Research Foundation, the Berth von Kantzow Foundation, and Region Stockholm
Zitieren
APA
Giesecke, J., Oskarsson, A., Petersson, M., Nordenvall, A. S., Tettamanti, G., Nordgren, A., & Höybye, C. (2025). Comorbidities, Endocrine Medications, and Mortality in Prader–Willi Syndrome—A Swedish Register Study. Journal of Clinical Medicine, 14(4), 1307. https://doi.org/10.3390/jcm14041307
Vancouver
Giesecke J, Oskarsson A, Petersson M, Nordenvall AS, Tettamanti G, Nordgren A, et al. Comorbidities, Endocrine Medications, and Mortality in Prader–Willi Syndrome—A Swedish Register Study. Journal of Clinical Medicine. 2025;14(4):1307. doi:10.3390/jcm14041307
BibTeX
@article{Giesecke2025,
author = {Giesecke, Julia and Oskarsson, Anna and Petersson, Maria and Nordenvall, Anna Skarin and Tettamanti, Giorgio and Nordgren, Ann and Höybye, Charlotte},
title = {Comorbidities, Endocrine Medications, and Mortality in Prader–Willi Syndrome—A Swedish Register Study},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {4},
pages = {1307},
doi = {10.3390/jcm14041307}
}
EUVIMED